Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CalciMedica, Inc.CALC · Entity 7804 | Chief Scientific Officer | September 24, 2026 | September 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CalciMedica, Inc.
Report date September 24, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2036-09-23 | Direct | 180,000 |
Reported balance
After 2026-09-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-24 · Grant · Acquired 180,000 · Balance 180,000 F1: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 28, 2026 20:28 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001969388-26-000003 · form4-09282026_080937.xml · derivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2036-09-23 F1 · derivative.exercise_date: Beginning September 24, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four year period. Read SEC document |
| July 28, 2025 Filed Jul 29, 2025 20:52 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $3.96 | $3,960.00 |
DisclosureSEC source: 0001415889-25-020458 · form4-07292025_040701.xml · nonDerivative · entry 2 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,944 Read SEC document |
| July 25, 2025 Filed Jul 29, 2025 20:52 UTC | CalciMedica, Inc. CALC · Entity 7804 | SaleCommon Stock | 1,000 | $3.65 | $3,650.00 |
DisclosureSEC source: 0001415889-25-020458 · form4-07292025_040701.xml · nonDerivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · kind: The sale of the common stock of CalciMedica, Inc. (the "Issuer") by the spouse of the reporting person reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 with the purchase of 1,000 shares of the Issuer's common stock by the reporting person's spouse at a price of $1.85 per share on July 1, 2025. The reporting person has agreed to pay to the Issuer upon settlement of the sale, $1,799.83, representing the full amount of the profit realized in connection with the short-swing transaction, less transaction costs. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 01:48 UTC | CalciMedica, Inc. CALC · Entity 7804 | PurchaseCommon Stock | 1,000 | $1.85 | $1,850.00 |
DisclosureSEC source: 0001415889-25-019190 · form4-07032025_010721.xml · nonDerivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 1,000 Read SEC document |
| June 24, 2025 Filed Jun 26, 2025 22:29 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 47,125 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-018308 · form4-06262025_100610.xml · derivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,125 Underlying: Common Stock · 47,125 shares Expires 2035-04-22 F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| April 23, 2025 Filed Apr 25, 2025 20:34 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001415889-25-011362 · form4-04252025_080402.xml · derivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2035-04-22 F1 · derivative.exercise_date: Beginning March 26, 2025, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period. Read SEC document |
| April 05, 2025 Filed Apr 8, 2026 01:50 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 65,124 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001969388-26-000002 · form4-04072026_090404.xml · derivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,124 Underlying: Common Stock · 65,124 shares Expires 2036-04-04 F1 · derivative.exercise_date: Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over a four year period, provided, however, that no shares shall vest until the filing of the Company's registration statement on Form S-8 covering the shares of Common Stock that were automatically added to the shares authorized for issuance under the Company's 2023 Equity Incentive Plan on January 1, 2026 pursuant to an annual "evergreen" provision. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 23:10 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-022503 · form4-08282024_110845.xml · derivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2034-08-26 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following March 28, 2024. Read SEC document |
| March 28, 2024 Filed Apr 23, 2024 01:39 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001415889-24-011348 · form4-04232024_010428.xml · derivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2034-03-27 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| May 08, 2023 Filed May 10, 2023 22:17 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (Right to Buy) · Derivative | 68,988 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001209191-23-028547 · doc4.xml · derivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,988 Underlying: Common Stock · 68,988 shares Expires 2033-05-07 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments over a four year period following the date of grant. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 1,877 | Not disclosed Strike: $17.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 13 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,877 Underlying: Common Stock · 1,877 shares Expires 2023-03-19 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F17 · price: Received in exchange for a stock option to acquire 65,191 shares of common stock of CalciMedica pursuant to the Merger Agreement. F14 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 18,991 | Not disclosed Strike: $17.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 12 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,991 Underlying: Common Stock · 18,991 shares Expires 2033-03-19 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F16 · price: Received in exchange for a stock option to acquire 659,413 shares of common stock of CalciMedica pursuant to the Merger Agreement. F14 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 2,090 | Not disclosed Strike: $17.34 | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 11 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,090 Underlying: Common Stock · 2,090 shares Expires 2033-03-19 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F15 · price: Received in exchange for a stock option to acquire 72,589 shares of common stock of CalciMedica pursuant to the Merger Agreement. F14 · derivative.exercise_date: Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 1,954 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 10 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,954 Underlying: Common Stock · 1,954 shares Expires 2032-08-30 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F13 · price: Received in exchange for a stock option to acquire 67,873 shares of common stock of CalciMedica pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 661 | Not disclosed Strike: $10.42 | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 9 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 661 Underlying: Common Stock · 661 shares Expires 2032-08-30 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F12 · price: Received in exchange for a stock option to acquire 22,977 shares of common stock of CalciMedica pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 5,472 | Not disclosed Strike: $19.45 | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 8 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,472 Underlying: Common Stock · 5,472 shares Expires 2032-07-12 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F11 · price: Received in exchange for a stock option to acquire 190,000 shares of common stock of CalciMedica pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 7,264 | Not disclosed Strike: $7.99 | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 7 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,264 Underlying: Common Stock · 7,264 shares Expires 2031-06-30 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F9 · price: Received in exchange for a stock option to acquire 252,226 shares of common stock of CalciMedica pursuant to the Merger Agreement. F8 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 13,147 | Not disclosed Strike: $7.99 | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 6 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,147 Underlying: Common Stock · 13,147 shares Expires 2031-04-27 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F10 · price: Received in exchange for a stock option to acquire 456,522 shares of common stock of CalciMedica pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 7,264 | Not disclosed Strike: $7.99 | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 5 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,264 Underlying: Common Stock · 7,264 shares Expires 2031-04-27 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F9 · price: Received in exchange for a stock option to acquire 252,226 shares of common stock of CalciMedica pursuant to the Merger Agreement. F8 · derivative.exercise_date: Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 21,647 | Not disclosed Strike: $6.60 | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 4 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,647 Underlying: Common Stock · 21,647 shares Expires 2030-06-29 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F7 · price: Received in exchange for a stock option to acquire 751,649 shares of common stock of CalciMedica pursuant to the Merger Agreement. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on June 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 8,640 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 3 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,640 Underlying: Common Stock · 8,640 shares Expires 2029-04-24 F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F5 · price: Received in exchange for a stock option to acquire 300,000 shares of common stock of CalciMedica pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantEmployee Stock Option (right to buy) · Derivative | 22,777 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · derivative · entry 2 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,777 Underlying: Common Stock · 22,777 shares Expires 2028-08-01 F3 · price: Received in exchange for a stock option to acquire 790,880 shares of common stock of CalciMedica pursuant to the Merger Agreement. F4 · price: Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 20, 2023 Filed Mar 23, 2023 00:49 UTC | CalciMedica, Inc. CALC · Entity 7804 | GrantCommon Stock | 11,944 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-020679 · doc4.xml · nonDerivative · entry 1 Stauderman Kenneth A. · CIK 0001969388 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,944 F1 · price: Received in exchange for 414,706 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.